Uses and formulations of cannabinoids, in particular of cannabidiol, are provided.

The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS).

Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabigatran etexilate layer separated by a semipermeable film layer, and the semipermeable film layer comprises a water-soluble compound, a water-insoluble compound and an optional anti-sticking agent and/or plasticizer.

The present invention relates to a method for modifying release of a therapeutically active agent from an elastomeric matrix, comprising providing a core comprising an elastomeric matrix and a therapeutically active agent; dipping the core to a coating solution of an elastomer, wherein the elastomer comprises 20-35 wt-% of a filler, calculated from the total amount of filler and elastomer; curing the dipped core to provide a coated core. In this method the dipping is provided as a continuous process by pulling the core through the coating solution, using a pulling speed suitable for providing a coating thickness of δ-IOO the filler is selected from silica, titanium dioxide, barium sulphate, carbon and mixtures thereof; the elastomer comprised in the core and the elastomer comprised in the coating solution are independently selected from poly(dimethyl) siloxanes, polyethylene vinyl acetates (EVAs), polyurethanes (PUs), polyhydroxyethyl methacrylates (PHEMAs) and polymethyl methacrylates (PMMAs).

A method of treating non-small cell lung cancer in a mammal by administering to a patient a pharmaceutically acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1) wherein R.sup.1 is alkyl having a carbon number of 1-4, R.sup.2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R.sup.3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR.sup.5—(CH.sub.2).sub.m—R.sup.6 wherein R.sup.5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R.sup.6 is phenyl or pyridyl optionally substituted by a halogen atom; or —NR.sup.7—CO—(CH.sub.2).sub.n—R.sup.8 wherein R.sup.7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R.sup.8 is phenyl or pyridyl optionally substituted by a halogen atom, and R.sup.4 is —(CH.sub.2).sub.a—CO—NH—R.sup.9 wherein a is an integer of 1-4, and R.sup.9 is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH.sub.2).sub.b—COOR.sub.10 wherein b is an integer of 1-4, and R.sup.10 is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. ##STR00001##

A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.

Compositions and methods are provided for making hyper compliant polymer particles by inverse emulsification and having a predetermined mechanical compliance and a predetermined size with a monodisperse diameter. Compositions and methods are provided for use of hyper compliant polymer particles in drug delivery, assay, particle image velocimetry, ceramics, cosmetics, deconvolution, electronic paper, insulation, personal care, standards, retroreflective paint and paint applications, thickening agents, regenerative medicine, device calibration, micro-carriers and force indicators.

Provided herein are extended release polymers. In one aspect, a composition for sustained release of active ingredients comprises a block polymer having formula: PEG-PCL-PLA-PCL-PEG or PGA-PCL-PEG-PCL-PGA. The extended release block polymers modulate drug release rate based on the hydrophobicity of the PTSgel polymer irrespective of the nature of drug. PTSgel polymers are biodegradable, thermosensitive, and compatible with hydrophilic, hydrophobic, and combinations thereof, biologic or chemical active agents.

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.

The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

In certain embodiments, the present invention provides the use of microRNA (miR)-200a and/or miR-200c to inhibit ossification and bone formation. In certain embodiments, the present invention provides the use of miR-200a inhibitor to stimulate bone regeneration.